Podcasts about new therapies

Long COVID and sports injuries are becoming impossible to ignore—and this episode explores why more athletes may be dealing with fatigue, soft tissue breakdown, and prolonged recovery after viral illness. In this powerful conversation, Dr. Greg Jones sits down with Dr. Muhammad Mansour, a naturopathic doctor and regenerative medicine specialist who treats elite athletes at the highest levels.In this episode, you'll learn how long COVID may affect skeletal muscle, mitochondrial function, exercise tolerance, and systemic inflammation—and why these issues can persist even after the initial infection appears to resolve. Dr. Mansour explains how athletes can miss early warning signs, why “pushing through” fatigue may backfire, and how a more individualized recovery strategy may be critical in the post-pandemic era.If you're an athlete, coach, practitioner, or health-conscious listener trying to understand the intersection of long COVID, inflammation, and injury risk, this episode offers a science-informed perspective on what recovery may require now.

Lisa Salberg and Dr. Matt Martinez break down how medical management for HCM is rapidly evolving, from traditional beta blockers to game-changing myosin inhibitors. They also preview what's next, including emerging drugs, clinical trials, and new approaches that could reshape care in the near future.   This conversation was recorded May 1, 2026

Pharma and tech companies are working more closely together than ever. As proven by the news of Merck and NVidia's new partnership, for example. But while the idea of using AI for drug discovery has been around for a while now, patient access has an awfully long way to catch up to the promise of these new therapies. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dean Erhardt, founder of D2 Solutions, an end-to-end strategic partner delivering industry-leading consulting and purpose-built technologies to pharma manufacturers, hospitals, pharmacies, payers & PBMs. The conversation focuses on the disconnect between distributions, reimbursements, and patient services, particularly when it comes to speciality medicines, as well as patient access today versus the state of patient access tomorrow, and the benefit or otherwise of price protection guarantees with PBMs, when it comes to new therapies. You can listen to episode 256 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Lisa Salberg and Dr. Marty Maron break down the latest HCM developments from ACC, including emerging myosin inhibitors, AI in imaging, and new approaches to fibrosis and genetic therapies. They also explain what these advances mean for patients now and how to prepare for a rapidly evolving treatment landscape.   This conversation was record April 10, 2026

In this episode of the LiverHealthPOD, John, will and Paul discuss new breakthrough treatments in PBCFor decades, treatment for primary biliary cholangitis (PBC) centred on ursodeoxycholic acid (UDCA or "Urso"). But the therapeutic landscape is rapidly evolving.In this episode of LiverHealthPOD, we explore the emerging wave of treatments transforming care for PBC. What do these therapies mean for patients who don't respond adequately to standard treatment? How do clinicians decide when to escalate therapy? And what might the future hold for disease modification in PBC?Join us as we unpack the latest science and clinical advances shaping the next chapter in PBC care.Don't forget to send through any questions (about the liver) to Liverhealthpod@gmail.com

Arthritis affects over 50 million people in the U.S. Dr. Thomas Buchheit, a specialist in regenerative and auto-biologic treatments for joint and nerve pain, discusses new therapies to heal joints and nerves, reduce pain, and restore function. Dr. Buccheit is founder of Triangle Regen Medicine and Biologics Center in Chapel Hill, N.C. and adjunct associate professor at Duke University. He is author of Healing Joints and Nerves: Immune Stimulation and the New Science of Regenerative Therapies.Fearless Fabulous You is broadcast live Wednesdays at 12 Noon ET on W4WN Radio - Women 4 Women Network (www.w4wn.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com).   Fearless Fabulous You Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.

Friday Headlines: At least 40 dead after fire at Swiss ski resort bar, More than 100 business leaders call for Royal Commission into Anti-Semitism, House prices are set to jump more than 5% in 2026, and Usman Khawaja's Test future is up in the air leading into the Sydney test. Deep Dive: When you book in with a psychologist, how much do you really know about the kind of treatment you’ll receive? While cognitive behavioural therapy is one of the most common approaches, new and emerging therapies are constantly being developed. But how do these therapies move from theory into real-world practice and how long does that process take? In this episode of The Briefing, Helen Smith is joined by Kelvin Wong, Senior Lecturer in the Department of Psychological Sciences at Swinburne University of Technology, who unpacks new therapies for 2026 and when someone should consider seeking therapy in the first place. Follow The Briefing: TikTok: @thebriefingpodInstagram: @thebriefingpodcast YouTube: @TheBriefingPodcastFacebook: @thebriefingpodcastSee omnystudio.com/listener for privacy information.

In this episode, Catherine Glass is joined by Anna Minchom, Clinical Scientist at the Drug Development Unit at the Royal Marsden Hospital and the Institute of Cancer Research, London, UK. In a highly informative discussion, Minchom explains the drug development process, key considerations in designing and conducting a trial, and the challenges in drug resistance.   Timestamps:      00:00 – Introduction 00:51 – Her journey into oncology 4:04 – Drug development 07:20 – Patient recruitment 08:45 – Challenges of drug resistance 11:20 – Early-phase clinical trials 13:06 – Navigating clinical trial outcomes 15:38 – Emerging technologies and therapies 17:42 – Side effects 19:09 – Three magic wishes

Learn which HER2-targeted therapies are being evaluated for the first-line treatment of gastroesophageal adenocarcinoma. Credit available for this activity expires: 11/27/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/her2-evolution-gastroesophageal-cancer-new-therapies-and-2025a1000x2t?ecd=bdc_podcast_libsyn_mscpedu

Matias interviews Rob Malenka, Chief Scientific Officer of Bayshore, the family office of Google co-founder Sergey Brin.  Bayshore has played a major role in advancing treatments for Parkinson's, bipolar, and autism. In this episode, we discuss:Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneousThe bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma's avoidance of neuropsychiatryHow breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropyHow success depends on mission-driven, ethical people who align science, capital, and patient impact.The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.Credits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky Produced by Caitlin Ner & Nico V. Rey Find us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In this episode, Dr. Rena Malik is joined by Dr. Mohit Khera to explore cutting-edge regenerative therapies for erectile dysfunction. Together, they unpack the latest research on treatments such as hyperbaric oxygen therapy, shockwave therapy, stem cells, PRP, Botox, and radiofrequency, emphasizing both the promise and limitations of these innovative approaches. The discussion offers listeners expert perspectives on the science behind each therapy, their current investigational status, practical considerations, and potential side effects. Become a Member to Receive Exclusive Content: renamalik.supercast.com Schedule an appointment with me: https://www.renamalikmd.com/appointments ▶️Chapters: 00:00 Hyperbaric Oxygen for ED 03:00 Shockwave Therapy Evidence 04:43 Stem Cell Trials and Shockwave 05:25 Efficacy, Maintenance, and Counseling 06:54 Other Shockwave Applications 08:47 Radiofrequency for ED 10:49 PRP, Botox, and Supplements Stay connected with Dr. Mohit Khera on social media for daily insights and updates. Don't miss out—follow him now and check out these links! INSTAGRAM - https://www.instagram.com/drmohitkhera/?hl=en X - https://x.com/drmohitkhera?lang=en WEBSITE - https://drmohitkhera.com/ Let's Connect!: WEBSITE: http://www.renamalikmd.com YOUTUBE: https://www.youtube.com/@RenaMalikMD INSTAGRAM: http://www.instagram.com/RenaMalikMD TWITTER: http://twitter.com/RenaMalikMD FACEBOOK: https://www.facebook.com/RenaMalikMD/ LINKEDIN: https://www.linkedin.com/in/renadmalik PINTEREST: https://www.pinterest.com/renamalikmd/ TIKTOK: https://www.tiktok.com/RenaMalikMD ------------------------------------------------------ DISCLAIMER: This podcast is purely educational and does not constitute medical advice. The content of this podcast is my personal opinion, and not that of my employer(s). Use of this information is at your own risk. Rena Malik, M.D. will not assume any liability for any direct or indirect losses or damages that may result from the use of information contained in this podcast including but not limited to economic loss, injury, illness or death. Learn more about your ad choices. Visit megaphone.fm/adchoices

Novartis has agreed to license and develop Arrowhead Pharmaceuticals' preclinical stage small interfering RNA (siRNA) therapy ARO-SNCA, a potential treatment for Parkinson's disease and other synucleinopathies, plus additional targets. Two stories this week covered very different types of cell reprogramming techniques for therapy development. The first approach may overcome the time delays and safety risks of traditional immunotherapies, especially for patients with aggressive, late-stage disease. Meanwhile, electrical stimulation of macrophages could represent a new therapy to boost the body's own repair processes in a range of injury and disease situations. Finally, Eli Lilly saw its shares climb 5% this past week after announcing that its history-making oral obesity candidate, orforglipron, aced the Phase III ATTAIN-2 trial. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.Listed below are links to the GEN stories referenced in this episode of Touching Base:The State of Biotech Summit RegistrationNovartis Commits Up to $2.2B toward Developing Arrowhead siRNA TherapyAlex Philippidis, GEN Edge, September 2, 2025Off-the-Shelf Immunotherapy Demonstrates Multipronged Attack Against CancerGEN, August 29, 2025Human Macrophages “Reprogrammed” by Electrical Stimulation to Encourage Faster HealingGEN, September 2, 2025StockWatch: Analysts See $10B+ in Sales for Lilly Oral GLP-1Alex Philippidis, GEN Edge, September 1, 2025Touching Base PodcastHosted by Corinna Singleman, PhDBehind the BreakthroughsHosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

A single gene that reverses ageing by over 13 years without activating pluripotency or cancer risk? Shift Bioscience may have cracked the code with SB000, an AI-discovered gene that could revolutionise how we approach ageing, rejuvenation, and gene therapy. In this detailed breakdown, Lisa Tamati, longevity coach, biohacker, and host of the Longevity & Lifestyle podcast Pushing The Limits, explores how SB000 was discovered using cutting-edge AI and transcriptomic ageing clocks, what it actually does at the cellular level, and what this means for the future of safe, targeted anti-aging interventions. What you'll learn in this episode: How cell age reversal has become a real possibility Why Yamanaka factors (OSKM) carry cancer risk How Shift Bioscience used AI to simulate 562 million gene combinations What makes SB000 unique as a “transcriptomic rejuvenator” The therapeutic potential of SB000 in reversing ageing safely Why this matters for the future of biohacking, longevity science, and gene therapy Visit Shift Biosciences to learn more about this study: https://www.shiftbioscience.com/

Dominate C. diff! Learn to distinguish colonization from infection, select first-line therapies, and counsel patients on recurrence prevention and microbiome recovery. We're joined by IDSA past president and expert on foodborne and intestinal infections, Dr. Cindy Sears (Johns Hopkins University) for a comprehensive update on Clostridioides difficile (C. diff, Cdiff, CDAD, CDI). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Intro 03:00 Guest bio and hobby 04:25 Case of Charles Fleur Fontaine 06:00 Risk factors and epidemiology 08:00 Antibiotic hierarchy of risk 10:00 Diagnosis, testing strategies 14:00 Defining severity 17:30 Treatment options 20:00 Microbiome recovery strategies 24:00 Probiotics and postbiotics 27:00 Infection control counseling 30:00 C. diff and colon cancer 32:00 Recurrent C. diff strategies 35:00 Why some FMT and bezlotoxumab were discontinued 38:00 Microbiota replacement therapies 43:00 Prophylaxis strategies 45:00 Future therapies and ongoing research 47:00 Audience Q&A 52:00 Outro Credits Written and Produced by: Matthew Watto, MD, FACP  Cover Art and Infographic by: Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Cynthia Sears MD Disclosures Dr. Sears reports no relevant financial disclosures. Dr. Williams financial relationships disclosed include a Merck grant or research support. This relationship has not ended. Sponsor: Mint Mobile  This year, skip breaking a sweat AND breaking the bank. Get this new customer offer and your 3-month Unlimited wireless plan for just 15 bucks a month at mintmobile.com/CURB  Sponsor: Panacea Financial Let Panacea Financial take the financial stress off your plate,so you can get back to doing what matters most. Visit panaceafinancial.com  Sponsor: FIGS Get15% off your first order at wearfigs.com with the code FIGSRX

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35991/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35991/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

Angela Hirbe, Associate Professor of Medicine at Wash U, and Director of the Adult Neurofibromatosis Clinical Program, and Pastor Austin, a person living with the condition, joins Megan Lynch with a look at some breakthrough therapies.

CME credits: 1.25 Valid until: 30-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-new-therapies-into-healthcare/35553/ Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

CME credits: 1.25 Valid until: 30-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-new-therapies-into-healthcare/35553/ Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

The Promise of Discovery Season 5, Episode 3 Neurofibromatosis Type 1 (NF1) is a neurodevelopmental disease which affects about 100,000 people in the US. Around 80% of these patients experience cognitive and intellectual impairments which are unaffected by currently approved therapies for NF1. A recent genetic study from our lab identified an association between the NF1 disease and a receptor protein called metabotropic glutamate receptor 7 (mGlu7). This project investigates how using small molecules to augment mGlu7 function could help identify new therapies for NF1 patients struggling with cognitive impairments. Featuring: Harrison Parent, Ph.D. Candidate- Niswender Lab, Department of Pharmacology, Vanderbilt University School of Medicine Interviewer: Colleen Niswender, Ph.D., Associate Professor of Pharmacology; Director of Molecular Pharmacology, Warren Center for Neuroscience Drug Discovery, and a Vanderbilt Kennedy Center Member

Dr. Thomas Chen is a world-renowned neurosurgeon, Director of Surgical Neuro-Oncology at the University of Southern California, and the founder and CEO of NeOnc Technologies. In this podcast episode we discuss the company's unique approach to treating glioblastoma and other aggressive brain cancers.

Dr. Ruchira Singh is an Associate Professor and the recipient of the Dean's Professorship in the Department of Ophthalmology at the University of Rochester Medical Center where she also has joint appointments in the Department of Biomedical Genetics and the Center for Visual Science. Ruchira studies eye diseases to understand why some people can't see as well as others, and the knowledge gained can be used to develop new treatments for diseases like age-related macular degeneration and Batten disease, which can cause blindness. When she's not working, Ruchira loves spending time with her two kids. Even the small, everyday moments they spend together doing things like going to McDonalds, the park, or their local library bring her so much joy. Ruchira received a bachelor's degree in computer science from Jawaharlal Nehru Technological University (JNTU) in India, and she completed her graduate studies in Physiology at Kansas State University. Next, Ruchira conducted postdoctoral research in Pharmacology at Yale School of Medicine, followed by a postdoc position in stem cell research at the University of Wisconsin-Madison. She joined the faculty at the University of Rochester in 2014. In this interview, Ruchira discusses her life and science.

Dr. Valentin, radiologist, discusses liver cancer and how the therapy of the TheraSphere Y-90 Glass Microspheres works to help treat cancer in the liver. He will cover how your liver functions, types of liver cancer and the latest treatment options for liver cancer.

Tinnitus remains one of otology's greatest, most challenging, and unsolved clinical problems. In this episode of the BackTable ENT Podcast, Dr. Hamid Djalilian, chair of otolaryngology at University of California Irvine (UCI), joins guest host and fellow otologist Dr. Walter Kutz (UT Southwestern) to discuss contemporary tinnitus therapy. --- This podcast is supported by: PearsonRavitz https://pearsonravitz.com/backtable --- SYNPOSIS First, Dr. Djalilian shares how he got interested in tinnitus. After observing how migraines and tinnitus share many similar triggers, he hypothesized that increased central sensitivity underlies both diseases. He successfully adopted migraine management strategies for his tinnitus patients and found great clinical success. After sharing pathophysiologic similarities between the two diseases, Dr. Djalilian expounds on how he evaluates and treats tinnitus. His discussion includes lifestyle modifications, medication, and emerging surgical therapies. Finally, he advises listeners to think of tinnitus as a manageable condition, rather than a poorly-understood phenomenon. --- TIMESTAMPS 00:00 - Introduction 02:34 - The Challenge of Treating Tinnitus 07:19 - Connecting Tinnitus & Migraine 15:59 - Atypical (Otologic) Migraine & Diagnostic Challenges 19:59 - Managing Tinnitus Triggers 26:27 - Dietary Triggers of Tinnitus 28:44 - The Role of Sleep Quality in Tinnitus 33:04 - Caring for Older Patients with Tinnitus 37:59 - New Therapies for Tinnitus: Sound & Cognitive Behavioral Therapy 44:08 - Neuromodulation: The Future of Tinnitus Therapy? 51:34 - Final Thoughts on Tinnitus Treatment --- RESOURCES BackTable ENT Episode 60 Otologic Manifestations of Migraine with Dr. Hamid Djalilian https://www.backtable.com/shows/ent/podcasts/60/otologic-manifestations-of-migraine Dr. Hamid Djalilian University of California, Irvine Profile: https://www.ent.uci.edu/faculty/hamid-djalilian-md.asp Dr. Hamid Djalilian's Website: https://hamiddjalilianmd.com/ Fan-Gang Zeng (Hearing and Speech) Lab at UCI: https://faculty.sites.uci.edu/hesplab/ PearsonRavitz: https://pearsonravitz.com/

Staying abreast of recent clinical practice guidelines for the management of relapsed/refractory mantle cell lymphoma can be challenging for providers who may seldom encounter it in community practice. In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population. “Fortunately, treatments such as BTK inhibitors are generally very well tolerated by patients, and there are very few patients who can't take a BTK inhibitor. But as you go up the scale of increasing intensity, such as CAR T-cell, or even allogeneic stem cell transplantation, those are therapies not suitable for patients with more extensive comorbidities.” – Dr. Jeff Sharman, MD   “A collaborative relationship between a community practice and an academic center can be of considerable benefit to a patient, so that as treatment decisions are made, both the physician and patient can feel like they're offering the patient the very best therapy.” – Dr. Jeff Sharman, MD    Jeff Sharman, MD  Medical Director of Hematology Research, US Oncology Director of Research Willamette Valley Cancer Institute Eugene, Oregon    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy The CAR T-cell Therapy Process Patient-Caregiver CAR T-cell Therapy Facts Learn About CAR T-cell Therapy Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society

Send us a textIn this Ones Ready Podcast episode, Aaron and Peaches sit down with Dr. Tim Vermillion to explore essential topics on mental health, stress management, and support for military veterans. Dr. Vermillion shares his personal journey from the military to becoming a therapist, offering valuable insights into the impact of stress on the body and mind. They delve into the importance of breath work, physical activity, and the early signs of unhealthy coping mechanisms. Dr. Vermillion explains therapeutic approaches like cognitive behavioral therapy (CBT) and eye movement desensitization and reprocessing (EMDR) for treating PTSD.The conversation also touches on groundbreaking treatments, including psychedelic therapies, hyperbaric therapy, and transmagnetic stimulation, with a focus on the VA's ongoing research. Dr. Vermillion emphasizes the critical role of active listening, non-confrontational support, and the military's efforts to destigmatize mental health struggles. He encourages veterans to seek help and be open about their challenges, offering hope through new and evolving therapies.Chapters00:00 Introduction and Background09:45 Understanding Stress and Its Management18:29 The Role of Breath Work and Physical Activity22:18 Recognizing Early Warning Signs of Unhealthy Coping26:23 Treating PTSD with CBT and EMDR32:23 Expanding Stress Tolerance34:18 Supporting Others in Managing Stress and Trauma34:31 Supporting Veterans' Mental Health36:05 Active Listening and Non-Confrontational Approaches37:02 Avoiding Directive Language38:09 Substances and Inhibiting the Healing Process40:29 Self-Medication and Negative Effects41:35 Comparing Substances: Alcohol, Tobacco, and Marijuana48:07 Destigmatizing Mental Health in the Military51:47 Following Mentors and Gaining Tacit KnowledgeSupport the showJoin this channel to get access to perks:https://www.youtube.com/channel/UC9aFBBZoBcQk8UUN_pO7nDA/joinBuzzsprout Subscription page: https://www.buzzsprout.com/680894/subscribeCollabs:Ones Ready - OnesReady.com 18A Fitness - Promo Code: 1ReadyATACLete - Follow the URL (no promo code): ATACLeteCardoMax - Promo Code: ONESREADYHoist - Promo Code: ONESREADYThe content provided is for informational purposes only and does not constitute legal advice. The host, guests, and affiliated entities do not guarantee the accuracy or completeness of the information provided. The use of this podcast does not create an attorney-client relationship, and the podcast is not liable for any damages resulting from its use. Any mention of products or individuals does not constitute an endorsement. All content is protected by intellectual property laws....

The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.  “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP   “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC Nirav Shah, MD, MSHP  Associate Professor of Medicine  Medical College of Wisconsin  Division of Hematology and Oncology  Milwaukee, Wisconsin    Kirollos Hanna, PharmD, BCPS, PCOP, FACCC  Assistant Professor of Pharmacy, Mayo Clinic  Director of Pharmacy  Minnesota Oncology   St. Paul, Minnesota    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf   The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf   Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf   Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf    Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society  https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf   

The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma. “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP   “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC     Nirav Shah, MD, MSHP  Associate Professor of Medicine  Medical College of Wisconsin  Division of Hematology and Oncology  Milwaukee, Wisconsin    Kirollos Hanna, PharmD, BCPS, PCOP, FACCC  Assistant Professor of Pharmacy, Mayo Clinic  Director of Pharmacy  Minnesota Oncology   St. Paul, Minnesota    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf   The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf   Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf   Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf    Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society  https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf         

This is the second episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "New Therapies and Expert Strategies for Long-term Control", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics: The pros and cons of steroid use in treating AD Targeted non-steroidal topical therapies approved by the FDA Relevant clinical efficacy and safety data for new and emerging non-steroidal topicals Recommendations for long-term symptom control in AD patients

In this episode of Causes or Cures, Dr. Eeks chats with cardiologist, physician-scientist and CEO of Fractyl Health Dr. Harith Rajagopalan about solutions his company is developing for the problem of keeping weight off after someone stops taking the obesity/weight loss medication, such as Ozempic. Dr. Rajagopalan explains the issue of weight rebound after stopping the medication, and describes two new therapies Fractyl Health is developing that would allow a person to sustain weight loss without the need for ongoing medication. He also provides an overview of the multifaceted approach necessary for tackling obesity and offers a unique perspective on chronic disease.  You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here. Support the Show.

Full show notes: https://syngap.fund/n142    BIG NHS UPDATE 66 Kids evaluated, 11 have had follow-ups, ~20 new kids scheduled. Colorado should start seeing patients in August! WHERE TO DONATE MONEY: MDBR is next week, donate now! https://charity.pledgeit.org/t/jY577u7uMc Thanks to the team. https://Syngap.Fund/Unite   BLOOD: June 7 & 8, Loews Coronado Bay Resort, email CSO@cureSYNGAP1.org TIME TO JOIN #TEAMSRF  - Volunteer Webinar: https://syngap.fund/LT - Fifty families lent their good names to SRF in this wonderful blog: https://syngap.fund/Community   - https://curesyngap1.org/volunteer-with-srf/    CHATS WITH INDUSTRY  - Is IT delivery a blocker for precision therapies, NO!  - 2026 is feeling like the earliest we see trials.  - BIO with Kathryn next week! CALENDAR MANAGEMENT Rare Across America is 66 days away, register now: https://everylifefoundation.org/rare-advocates/rare-across-america/    Conference is 188 days away: https://curesyngap1.org/events/conferences/syngap1-conference-2024/   PUBLICATION ALERT https://x.com/cureSYNGAP1/status/1795837761678962799    NEWLY DIAGNOSED? New families have resources here! https://syngap.fund/Resources SOCIAL MATTERS - AMPLIFY SRF TO MAKE SURE FAMILIES FIND US  - 1,020 YouTube.  https://www.youtube.com/@CureSYNGAP1   - 10,000 Twitter https://twitter.com/cureSYNGAP1  - 3,591 LinkedIn.  https://www.linkedin.com/company/curesyngap1/ - 49k Insta https://www.instagram.com/curesyngap1/ - 392 TikTok https://www.tiktok.com/@curesyngap1 Podcasts, give all of these a five star review! SRF Channel - https://podcasts.apple.com/us/channel/syngap1-podcasts-by-srf/id6464522917 Episode 142 of #Syngap10 - May 31, 2024 #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #GeneChat #F78A1 #CureSYNGAP1

In this episode, Dr. Daniel Llano leads a discussion focusing on new therapy options for dementia patients.

There are developments in the world of men's health in erectile dysfunction and testosterone. As always Ray and I are dedicated to delivering the latest news and technology and today men's health gets a boost.     See omnystudio.com/listener for privacy information.

Remarkable progress has been made in the treatment of myeloma over the past decade, giving patients and families much hope… The post How New Therapies Are Changing The Future of Myeloma first appeared on The Bloodline with LLS.

Remarkable progress has been made in the treatment of myeloma over the past decade, giving patients and families much hope… The post How New Therapies Are Changing The Future of Myeloma first appeared on The Bloodline with LLS. The post How New Therapies Are Changing The Future of Myeloma appeared first on The Bloodline with LLS.

IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD by Gastroenterology Learning Network

Featuring perspectives from Dr Richard T Penson and Dr Krishnansu S Tewari, including the following topics: Introduction: Pan-tumor Indications for New Therapies (0:00) Endometrial Cancer (14:13) Treatment of Cervical Cancer (32:38) Updates in Ovarian Cancer (45:41) CME information and select publications

How do retina specialists introduce new therapies to patients, and how does thoughtful use of imaging help providers integrate new treatments into their clinics? Moderator Aleksandra Rachitskaya, MD, joins panelists Mrinali Gupta, MD, and Katherine Talcott, MD, to review how innovations in imaging software have helped onboard GA therapies in real-world clinics. This episode is sponsored by ZEISS.

Drs Sandhya Srinivas and Oliver Sartor discuss the VISION study, new therapies for patients with metastatic castrate-resistant prostate cancer, and PSMA biomarker-based imaging. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988736). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Lutetium-177-PSMA-617 for Metastatic Castration-resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/34161051/ Prostate Cancer Theranostics: PSMA Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/34053583/ Piflufolastat F-18 (18F-DCFPyL) for PSMA PET Imaging in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/35603510/ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in Prostate Cancer https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients https://pubmed.ncbi.nlm.nih.gov/27765862/ Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression https://pubmed.ncbi.nlm.nih.gov/30425003/ Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients With Castration-resistant Prostate Cancer and Bone Metastases: Results From a Phase 3, Double-blind, Randomised Trial https://pubmed.ncbi.nlm.nih.gov/24836273/ Long-term Follow-up and Outcomes of Retreatment in an Expanded 50-patient Single-center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/31732676/ [177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/33581798/ Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-label Trial https://pubmed.ncbi.nlm.nih.gov/20888992/ [177Lu]Lu-PSMA-617 in PSMA-positive Metastatic Castration-resistant Prostate Cancer: Prior and Concomitant Treatment Subgroup Analyses of the VISION Trial https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.5001 PSMAfore: A Phase 3 Study to Compare 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-naïve Patients With Metastatic Castration-resistant Prostate Cancer https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.TPS211

New biological therapies like dupilumab target Type 2 inflammation, but new research shows they are also modifying the skin microbiome. In this episode we discuss what Type 2 inflammation is, why it matter in eczema, and how it modifies the microbiome. Our guest is Dr. Lisa Beck (Co-Director of the Center for Allergic Disease Research, University of Rochester Medical Center, NY) who has dedicated her 35 year career to understanding why some eczema patients are susceptible to skin infections and finding safe and effective eczema treatments.Research associated with this podcastType 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic DermatitisTralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitisRapid Reduction in Staphylococcus aureus in Atopic Dermatitis Subjects Following Dupilumab Treatment

Psoriasis, atopic dermatitis, vitiligo...when it comes to chronic skin conditions, it can feel like the odds are stacked against you. But don't despair! There's a new player in the field that is changing the game: the Janus Kinase (JAK) family!  JAK inhibitors are used in patients with skin and other conditions where the immune system is overactive and causing damage. Tune in to this week's podcast episode with Dr. Chovatia, where we dive deep into the science behind JAK inhibitors and how they're helping patients manage their symptoms. Connect with Dr. Chovatia :- Linkedin- @rajmdphd Twitter- @RajMDPhD

Episode Notes Drs. Emily Kirkpatrick, Paul Sax, and Jill Strayer join Dr. Rachel Britt to discuss their experiences using injectable long-acting antiretrovirals, especially cabotegravir/rilpivirine, in their clinics. Listen to learn not only about logistical challenges with these drugs, but also creative solutions to overcome them. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

Dr. Allen Davidoff is the founder and CEO of XORTX Therapeutics, exploring new therapies to treat progressive kidney disease. Educated at The University of Calgary, Allen has 15 years of drug development experience with a focus on clinical and regulatory developmental affairs in the US, Canada, Germany, Denmark, and India. Allen has a broad range of senior management experience in pharmaceutical research and development including involvement in two investigational new drug (“IND”) applications or supplemental IND's, two phase I studies, seven phase II studies, and one new drug application (NDA). Prior to forming XORTX, Allen was the Chief Scientific Officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. and Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp.  If you have questions regarding items discussed during this episode or would like more information about Kidney Solutions weekly Support Group, contact Kent at kent.bressler@kidneysolutions.org For more information about Kidney Solutions, visit them at www.kidneysolutions.org Host: Kent Bressler Producer: Jason Nunez

Dr. Lorenz Studer is the Director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Institute. His lab exploits recent advances in stem cell biology to develop new therapies for degenerative diseases and cancer. Their projects involve directing the fate and age of hPSCs, modeling diseases, and developing cell therapies. He talks about his journey into the stem cell field and co-founding BlueRock Therapeutics. He also discusses the challenges of developing cell therapies at scale, strategies to target cognition loss in Parkinson's disease, and combining basic and translational research.

Joe Selvaggi talks with Pioneer Institute's Senior Fellow Dr. Bill Smith about the changes to drug pricing laws included in the recently passed Inflation Reduction Act. They discuss the legislation’s provisions, and who wins and loses as drug companies announce their response to the new law. Guest: William S. Smith is Visiting Fellow in Life […]

Joe Selvaggi talks with Pioneer Institute's senior fellow Dr. Bill Smith about the changes to drug pricing laws included in the recently passed Inflation Reduction Act provisions and discuss who wins and loses as drug companies announce their response to new law.

In the first hour of "Connections with Evan Dawson" on Wednesday, November 23, 2022, the team from a company called NeuroGenesis discusses a developing therapy that may be able to treat neurodegenerative diseases like MS and ALS.

Communication between the digestive system and brain is much more intricate than previously thought.  The digestive epithelium is laced with sensors that monitor the contents of the gut, reporting back to the brain, stimulating appropriate hormones and digestive action to guide motility, chemistry, and absorption. This network is frequently referred to as the 'second brain' because of the dense neurophysiology at work. Recently it has been hypothesized that dysfunction in the gut-brain axis may be the basis for several immune and neurological disorders, suggesting that this neurological system may be an excellent drug target. Nancy Thornberry, CEO and Founder of Kallyope (Cal-EE-O-pay) describes the gut-brain axis, its role in digestive signaling, her company's novel drug discovery methods, and potential drug targets that may lead to innovative therapies for human health originating here in the second brain.